Kurin Inc., the inventor and manufacturer of 510(k)-cleared and patented Kurin® blood culture collection sets announced the hiring of Don Canal to the newly created position of Executive Vice President, Operations.
“Bringing Mr. Canal into Kurin is an important addition to our company,” said Bob Rogers, CEO of Kurin, Inc. “Demand for Kurin’s products is growing at a torrid rate. The addition of Mr. Canal demonstrates our commitment to excellence. Mr. Canal’s extensive medical device manufacturing, operations, and regulatory experience, including most recently our work together at Ivera Medical, builds on our ability to handle the rapidly increasing demand for Kurin.”
Kurin’s Initial Specimen Discard (KISD) technology is superior to currently marketed diversion technologies, requiring no user interaction with complicated manual manipulations. The Kurin Lock® automatically and passively corrals potential contaminants during blood culture collection. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays, and impacting larger community health issues, such as antimicrobial resistance and the life-threatening C. diff. infection.
About Kurin, Inc.
Kurin Corporation, a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.